• Store
  • COVID-19 Info
  • APHON Swag

Industry Relations Council

irc imageAPHON Industry Relations Council (IRC) participation is available to organizations and companies that support the goals and mission of APHON. Participation is available at two levels — Associate and Premier — each with its own fee structure and varying levels of opportunity to engage with the APHON audience.

IRC Benefits IRC Application

Premier Level Members

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Phone: 805.447.1000
Fax: 805.447.1010

Amgen is committed to unlocking biology's potential for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Visit the Amgen website

3170 Porter Dr
Palo Alto, CA 94304
Phone: 650.496.3777
Fax: 650.496.3781

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully and redefine what is possible. As a sleep medicine leader and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development and is focused on transforming biopharmaceutical discoveries into novel medicines.

Visit the Jazz Pharmaceuticals, Inc. website

200 Pier Four Blvd
Boston, MA 02210

We are a U.S. based biotech company serving patients and caregivers in oncology. Our deep commitment to patients is fundamental to our culture. We consistently engage with patients, caregivers, families, and organizations to fully understand the patient communities' needs. We can expand our knowledge on patient needs each day through ongoing partnerships with patient experts and advocacy groups. Through our Patient Engagement Program, acute lymphoblastic leukemia patients and families can access Servier's guidance and resources throughout the treatment and recovery process. At Servier, we know navigating an acute lymphoblastic leukemia diagnosis and managing a multi-agent chemotherapeutic regimen can be overwhelming for patients and caregivers.  Our Patient Engagement Managers can help. Former acute lymphoblastic leukemia patients and caregivers themselves, they work one-on-one with patients and their families, answering questions, providing emotional support, and directing them to key resources and support services. Servier also offers a Free Product Program; qualifying US citizens and having a financial need may be able to receive prescribed Servier products at no cost. Our Patient Advocacy Team is proud to work with organizations that share our goal to improve patient outcomes for those affected by acute lymphoblastic leukemia. Patient organizations provide valuable educational information and resources that improve the lives of those facing cancer.

841 Woburn St
Wilmington, MA 01887
Phone: 781.935.8141

Azurity Pharmaceuticals, Inc. is leading the development and commercialization of innovative pediatric medications that offer dosing accuracy, safety, and availability. We are dedicated to improving the quality, accessibility, and delivery of FDA-approved medications for children and committed to making a difference in pediatric patients' lives.

Visit Azurity Pharmaceuticals, Inc. website

55 TW Alexander Dr.
Research Triangle Park, NC 27709
Phone: 919.485.8350
Fax: 919.485.8352

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Visit the United Therapeutics website

230 Park Ave
New York, NY 10069
Phone: 347.324.6221

About Us.Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

Our Mission. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. The company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—that target tumors that express GD2 and B7-H3, respectively.*

At the Heart of Y-mAbs. Founder Thomas Gad’s commitment to innovation began when his daughter, Daniella, received treatment for high-risk euroblastoma at Memorial Sloan Kettering Cancer Center.

* The safety and efficacy of these products have not been established by health authorities. The products are investigational and have not been approved in the US or globally.

Visit the Y-mABs website

Associate Level

PO Box 1000
Montville, NJ 07045
Phone: 412.445.7817